Discovery could improve immune checkpoint inhibitor safety

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar brand names. However, for some patients, ICI cancer treatment can also prompt the immune system to attack heart tissue—a potentially lethal side effect.